Merck's Keytruda secures broader lung cancer approval

A broader group of patients with metastatic lung cancer can now receive Merck & Co.'s immunotherapy Keytruda as initial treatment, following the Food and Drug Administration's approval of the drug plus chemotherapy for previously untreated squamous non-small cell lung cancer (NSCLC) on Tuesday.